Pemphigus Vulgaris

🧠 Standard of Care & Symptoms

Pemphigus Vulgaris (PV) is a severe, chronic, potentially life-threatening autoimmune intraepidermal blistering disease of the skin and mucous membranes.

• Presentation: Key clinical features.
  • *Flaccid Blisters:* Fragile, thin-walled blisters that develop on normal-looking or erythematous skin. Because they are intraepidermal and lack a strong roof, they rupture easily, leaving large, painful, raw erosions that are slow to heal and highly susceptible to secondary bacterial infections.
  • *Mucosal Erosions:* In over 70% of cases, painful blisters develop first in the oral mucosa (mouth, throat), preceding skin lesions by months. They cause severe pain, interfering with eating, drinking, and swallowing. Can also affect nasal, conjunctival, and genital mucosa.
  • *Nikolsky Sign:* A crucial clinical diagnostic sign. Applying gentle lateral pressure with a finger to normal-appearing skin adjacent to a lesion causes the outer layer of the skin (epidermis) to slide off or blister.
  • *Asboe-Hansen Sign:* Applying direct vertical pressure to an intact flaccid blister causes the fluid to spread laterally, expanding the blister margin into surrounding skin.

🧬 Diagnostics & Desmoglein Acantholysis

Diagnosis is confirmed through skin biopsy, direct immunofluorescence (DIF), and autoantibody ELISA assays.

• Diagnostic Criteria: Clinical and laboratory assays.
  • Histopathology: Biopsy of a fresh blister reveals **intraepidermal clefting** immediately above the basal layer (suprabasilar clefting), with basal keratinocytes remaining attached to the basement membrane zone, resembling a row of "tombstones" (tombstoning).
  • Direct Immunofluorescence (DIF): DIF of perilesional skin shows intercellular IgG and C3 deposition in a characteristic net-like, "chicken-wire" pattern throughout the epidermis.
  • ELISA Assays: Serum ELISA testing detects autoantibodies targeting **Desmoglein 3 (Dsg3)** (present in mucosal disease) and **Desmoglein 1 (Dsg1)** (present in cutaneous disease).

Pathophysiology of Acantholysis

The intraepidermal blistering in PV is driven by autoantibodies targeting desmosomal adhesion proteins:

• Desmoglein Targeting: IgG autoantibodies (mainly IgG4 and IgG1 subclasses) target the extracellular domains of **Desmoglein 3 (Dsg3)** and **Desmoglein 1 (Dsg1)**. Desmogleins are transmembraneous glycoproteins that form the core of desmosomes, the intercellular junctions that hold keratinocytes together.
• Acantholysis: Antibody binding causes steric hindrance, preventing desmoglein molecules from binding to their partners on neighboring cells. Simultaneously, binding triggers intracellular signaling cascades (involving p38 MAPK and PKC) that lead to desmosomal disassembly.
• Blister Formation: Keratinocytes lose cell-to-cell adhesion and separate from one another, a process known as **acantholysis**. Because the basal keratinocytes remain anchored to the basement membrane zone by hemidesmosomes, the separation occurs immediately above them, creating the characteristic suprabasilar blister.

💊 Systemic Prednisone & Rituximab Therapy

Management focuses on rapid suppression of autoantibody production to induce clinical remission and promote healing of erosions.

First-Line Medical Therapy

• Systemic Corticosteroids: High-dose oral prednisone (0.5 to 1.5 mg/kg/day) is started immediately to achieve rapid control of active blistering. Steroids are gradually tapered over months as lesions clear.
• Rituximab (Gold Standard): Rituximab, an anti-CD20 monoclonal antibody, is now the first-line treatment combined with corticosteroids. It selectively depletes CD20+ B-lymphocytes, shutting down the production of new anti-Desmoglein autoantibodies. This therapy achieves high rates of complete remission and acts as a major steroid-sparing agent.
• Steroid-Sparing Immunosuppressants: Oral **Mycophenolate Mofetil** (MMF) or Azathioprine are used as maintenance therapies to prevent relapse and minimize long-term steroid toxicity.

Emergency & Crisis Care

• Plasmapheresis or IVIG: For severe, life-threatening, or refractory disease, Plasmapheresis (plasma exchange) or Intravenous Immunoglobulin (IVIG) is used to rapidly clear circulating autoantibodies from the bloodstream.

🔬 Active Clinical Trials

Clinical trials are currently evaluating next-generation oral Bruton's tyrosine kinase (BTK) inhibitors, FcRn blockers, and desmoglein-specific CAR-T cell therapies.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with Pemphigus Vulgaris, establish these clinical care pathways:

1. Confirm Desmoglein Subtype via ELISA: Verify if your disease is mucosal-dominant (anti-Dsg3 positive), cutaneous-dominant (anti-Dsg1 positive), or mucocutaneous (both positive).
2. Schedule Rituximab Infusions: Discuss first-line Rituximab therapy with your dermatologist to induce remission early and avoid prolonged steroid side effects.
3. Optimize Oral Mucosal Care: Use topical viscous lidocaine and non-alcohol mouthwashes to manage painful oral erosions before meals.
4. Practice Non-Adherent Wound Care: Apply thick bland emollients and use non-adherent dressings (like petrolatum gauze) on open skin erosions to prevent infection and promote epithelialization.

❓ Patient FAQ

Q: What is the difference between Pemphigus Vulgaris and Bullous Pemphigoid?
A: In Pemphigus Vulgaris, autoantibodies target desmogleins, causing cell separation *within* the epidermis (**intraepidermal acantholysis**), leading to very fragile, flaccid blisters that rupture easily. In Bullous Pemphigoid, autoantibodies target hemidesmosomes in the basement membrane zone, causing separation of the entire epidermis from the dermis (**subepidermal blistering**), resulting in tense, firm blisters that do not rupture easily and are associated with severe hives/pruritus.

Q: Why is PV considered life-threatening if it only affects the skin?
A: Before the advent of systemic corticosteroids and biologics, PV was almost universally fatal (with a mortality rate exceeding 90%). The loss of the epidermal barrier over large areas of the body leads to massive fluid and electrolyte loss (similar to severe thermal burns) and exposes raw dermal tissue to life-threatening bacterial sepsis.